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Background
Glucose metabolism disorders are common in extremely
low birth weight (ELBW) infants and are associated with
high morbidity and mortality [1-9]. This study was con-
ducted to evaluate the prevalence and risk factors asso-
ciated with both hypo and hyperglycemia in ELBW
infants.
Materials and methods
All inborn ELBW neonates admitted to our NICU dur-
ing a 5-year period were eligible for this retrospective
analysis. Exclusion criteria were: birth weight (BW) <400
grams, major congenital malformations, death during
the first 24 hours of life. Hypoglycemia was defined as
blood glucose level (BGL) ≤45 mg/dL; hyperglycemia as
BGL>240 mg/dL in a single determination or >180 mg/dL
in two determinations at 2-hour intervals. Continuous
intravenous insulin infusion was started after an ineffective
glucose restriction.
Results
Of 195 ELBW infants, 29 (14.8%) were excluded and
166 (GA 26.7 2.1 weeks, BW 751 152 grams) were ana-
lyzed and grouped to their BGL. Normoglycemia was
observed in 79 neonates (47.6%) (N-Group); 80 neonates
(52.4%) showed abnormal BGL: 21 (12.7%) were hypo-
glycemic (Hypo-Group), 53 (31.9%) hyperglycemic
(Hyper-Group) and 13 (7.8%) showed both hypoglyce-
mia and hyperglycemia (Hypo&Hyper-Group). Clinical
characteristics of the groups are reported in Table 1.
Hypo-Group respect to N-Group showed a higher rate
of small for gestational age (SGA) neonates (p=0.03).
Hyper-Group in comparison to N-Group showed a ten-
dency toward a lower GA (p=0.05), lower BW (p<0.001),
higher sepsis rate (p<0.001), higher rate of treatment
with inotropic agents (p=0.02), corticosteroids (p=0.006)
and nonsteroidal antiinflammatory drugs (p=0.01).
Hypo&Hyper-Group respect to N-Group showed similar
GA, lower BW (p<0.001), higher sepsis rate (p<0.01),
higher rate of inotropic treatment (p=0.04). Insulin was
administered in 35 neonates (66%) of Hyper-Group and
in 8 neonates (61.5%) of Hypo&Hyper-Group. Intraven-
tricular Hemorrhage ( IVH) rate was higher in Hyper-
Group and Hypo&Hyper-Group respect to N-Group
(p=0.002) as well as IVH grade3 (p=0.001 and p=0.02,
respectively).The rate of both Retinopathy of Prematur-
ity ( ROP) and ROP ≥stage 2 in survived neonates was
higher in Hyper-Group respect to N-Group (p=0.008
and p=0.002, respectively). Mortality was similar among
the groups (Table 2).
Conclusions
Among ELBW infants, hypoglycemia occurs more fre-
quently in SGA neonates, while hyperglycemia alone or
a marked variability of BGL (hypo and hyperglycaemia)
is more common in sick neonates. High rate of glucose
homeostasis disorders highlights the importance of care-
fully monitoring BGL in order to a prompt manage-
ment. Continuous glucose monitoring recently used in
neonates [10] might be a useful tool for monitoring glu-
cose changes also in ELBW neonates.
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Table 1 Demographic data and risk factors in the study groups
N-Group N=79 Hypo-Group N=21 Hyper-Group N=53 Hypo&Hyper-Group N=13
GA (wks), mean±SD 26.8±2.0 27.7±2.4 26.1±2.1 26.8±1.8
BW (g), mean±SD 808±136 719±140 695±146 692±140
Male, n (%) 17 (21.5) 10 (47.6) 26 (49.0) 8 (61.5)
SGA, n (%) 22 (27.8) 11 (52.3) 16 (30.1) 4 (30.7)
Apgar1 <6, n (%) 39 (49.3) 9 (42.8) 34 (64.1) 8 (61.5)
Apgar5 <6, n (%) 8 (10.1) 0 9 (16.9) 2 (15.3)
Intubation, n (%) 47 (59.4) 11 (52.3) 37 (69.8) 10 (76.9)
Antenatal Steroid, n (%) 64 (81.0) 17 (80.9) 41 (77.3) 12 (92.3)
RDS, n (%) 66 (83.5) 19 (90.4) 49 (92.4) 13 (100)
Sepsis, n (%) 16 (20.2) 4 (19.0) 32 (60.3) 7 (53.8)
Inotropic Agents, n (%) 26 (32.9) 6 (28.5) 28 (52.8) 8 (61.5)
Xanthines, n (%) 70 (88.6) 20 (95.2) 50 (94.3) 13 (100)
Postnatal Steroid, n (%) 11 (13.9) 3 (14.2) 18 (33.9) 3 (23.0)
NEC, n (%) 6 (7.5) 2 (9.5) 5 (9.4) 4 (30.7)
Medical treatment for PDA, n (%) 34 (43.0) 8 (38.0) 34 (64.1) 9 (69.2)
Surgical Procedures, n (%) 5 (6.3) 3 (14.2) 7 (13.2) 2 (3.7)
RDS: Respiratory Distress Syndrome; PDA: Patent Ductus Arteriosus; NEC: Necrotizing enterocolitis
Table 2 Complications and outcome in the study groups
N-Group N=79 Hypo-Group N=21 Hyper-Group N=53 Hypo&Hyper-Group N=13
IVH, n (%) 17 (21.5) 7 (33.3) 25 (47.1) 8 (61.5)
IVH (grade 3, n (%) 5 (6.3) 1 (4.7) 15 (28.3) 4 (30.7)
ROP all stages in the survivors, n (%) 49 of 61 (80.3) 10 of 16 (62.5) 35 of 35 (100) 7 of 8 (87.5)
ROP > stage 2 in the survivors, n (%) 35 of 71 (57.3) 9 of 16 (56.2) 35 of 35 (100) 6 of 8 (75)
Mortality, n (%) 18 (22.7) 5 (23.8) 18 (33.9) 6 (46.1)
IVH: IntraventricularHemorrhage; ROP: Retinopathy of Prematurity
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